7.2 Asthma Control Assessment Tools & Validated Questionnaires

Key Takeaways

  • Asthma control evaluates the present adequacy of therapeutic management and the degree to which clinical manifestations, functional limitations, and future adverse risks are minimized by current therapy.
  • The EPR-3 guidelines categorize asthma control into three distinct levels: Well Controlled, Not Well Controlled, and Very Poorly Controlled, utilizing the same dual domains of Impairment (2–4 week recall) and Risk.
  • The Asthma Control Test (ACT) is a validated 5-item self-administered tool for patients aged ≥12 years with scores ranging from 5 to 25; a score of ≤19 indicates inadequately controlled asthma, and its Minimal Clinically Important Difference (MCID) is 3.0 points.
  • The Childhood Asthma Control Test (c-ACT) is validated for pediatric patients aged 4 to 11 years, incorporating 4 child-answered pictorial questions (0–3 scale) and 3 parent-answered questions (0–5 scale) for a maximum score of 27, where a score ≤19 defines poorly controlled asthma.
  • The Asthma Control Questionnaire (ACQ) calculates a mean score on a 0 to 6 scale across symptoms, SABA use, and FEV1; scores ≤0.75 confirm well-controlled asthma, scores ≥1.50 confirm inadequately controlled asthma, and its MCID is 0.5 points.
Last updated: September 2026

7.2 Asthma Control Assessment Tools & Validated Questionnaires

Quick Answer: While asthma severity establishes baseline disease intensity prior to therapy, asthma control evaluates the present adequacy of management once therapy has begun. The NHLBI EPR-3 stratifies control into three categories: Well Controlled, Not Well Controlled, and Very Poorly Controlled. In routine clinical practice, validated standardized questionnaires provide rapid, objective measurement: the Asthma Control Test (ACT) (ages ≥12, scored 5–25, where ≤19 indicates poor control; MCID = 3.0 points), the Childhood ACT (c-ACT) (ages 4–11, scored 0–27, where ≤19 indicates poor control), and the Asthma Control Questionnaire (ACQ) (scored 0–6, where ≥1.50 indicates poor control; MCID = 0.5 points).

Assessing asthma control is the primary operational task during every routine follow-up visit. Uncontrolled asthma is associated with frequent school and work absenteeism, recurrent emergency department visits, progressive airway remodeling, and heightened risk of fatal exacerbations. Because patients frequently underreport symptoms due to chronic habituation—normalizing shortness of breath or subtle activity restriction—certified asthma educators must utilize objective clinical grids and validated numerical questionnaires rather than relying on informal open-ended inquiries such as "How has your breathing been?"


The EPR-3 Asthma Control Framework: Impairment and Risk

The EPR-3 assesses control across the identical dual domains used for severity: Impairment (recalling the prior 2 to 4 weeks) and Risk (evaluating future adverse outcomes). Overall control is assigned based on the most severe category in which any single parameter falls.

Clinical Components of Control Assessment

  1. Daytime Symptoms: Frequency of coughing, wheezing, or dyspnea.
  2. Nighttime Awakenings: Frequency of waking up due to asthma symptoms.
  3. Interference with Normal Activity: Perceived limitation in performing typical physical tasks, work, school, or sports.
  4. SABA Use for Symptom Relief: Frequency of rescue bronchodilator use (excluding pre-exercise prevention).
  5. Pulmonary Function (Ages ≥5 Years): Current FEV1 or peak expiratory flow (PEF) compared against the patient's personal best or predicted normal value.
  6. Risk of Exacerbations: Number of events requiring systemic corticosteroid bursts or hospitalization over the previous year.
  7. Treatment-Related Adverse Effects: Evaluation of local or systemic toxicities from medications (e.g., oral candidiasis, dysphonia, growth deceleration).

EPR-3 Asthma Control Assessment Grid

Age GroupControl LevelDaytime SymptomsNighttime AwakeningsActivity InterferenceSABA Use for ReliefLung Function (FEV1 or PEF)Exacerbations Requiring Oral Corticosteroids
≥12 Years & AdultsWell Controlled≤2 days/week≤2 times/monthNone≤2 days/week>80% predicted / personal best0 to 1 per year
Not Well Controlled>2 days/week1 to 3 times/weekSome limitation>2 days/week60% to 80% predicted / personal best≥2 per year
Very Poorly ControlledThroughout the day≥4 times/weekExtremely limitedSeveral times per day<60% predicted / personal best≥2 per year
5 to 11 YearsWell Controlled≤2 days/week≤1 time/monthNone≤2 days/week>80% predicted / personal best0 to 1 per year
Not Well Controlled>2 days/week≥2 times/monthSome limitation>2 days/week60% to 80% predicted / personal best≥2 per year
Very Poorly ControlledThroughout the day≥2 times/weekExtremely limitedSeveral times per day<60% predicted / personal best≥2 per year
0 to 4 YearsWell Controlled≤2 days/week≤1 time/monthNone≤2 days/weekNot Applicable0 to 1 per year
Not Well Controlled>2 days/week>1 time/monthSome limitation>2 days/weekNot Applicable2 to 3 per year
Very Poorly ControlledThroughout the day>1 time/weekExtremely limitedSeveral times per dayNot Applicable>3 per year

Validated Asthma Control Questionnaires

To standardize clinical evaluation, researchers have developed numerical self-administered questionnaires. Certified asthma educators must master the structure, target age, scoring metrics, cutoffs, and Minimal Clinically Important Differences (MCID) of each instrument.

1. Asthma Control Test (ACT)

  • Target Population: Patients aged 12 years and older (adolescents and adults).
  • Recall Window: Past 4 weeks.
  • Structure: 5 items evaluated on a 1-to-5 Likert scale:
    1. Interference with work, school, or home tasks.
    2. Frequency of shortness of breath.
    3. Frequency of nighttime awakenings or early morning awakenings.
    4. Frequency of rescue inhaler use.
    5. Patient's overall self-rating of asthma control.
  • Scoring & Interpretation (Range: 5 to 25):
    • 20 to 25: Well Controlled asthma.
    • 16 to 19: Not Well Controlled asthma.
    • 5 to 15: Very Poorly Controlled asthma.
    • Validated Cutoff: A score of ≤19 is the internationally recognized threshold indicating poorly or inadequately controlled asthma requiring clinical evaluation.
  • Minimal Clinically Important Difference (MCID): 3.0 points. A change of 3 or more points reflects a clinically meaningful improvement or deterioration that justifies a change in therapeutic decision-making.

2. Childhood Asthma Control Test (c-ACT)

  • Target Population: Pediatric patients aged 4 to 11 years.
  • Recall Window: Past 4 weeks.
  • Structure (7 Items Total): Combines child-reported perceptions and parent/caregiver observations:
    • Part 1 (Child-Completed, 4 Items): The child responds to 4 pictorial questions featuring cartoon faces depicting symptom severity (0 to 3 scale: 0 = worst/frowning face, 3 = best/smiling face) assessing feeling, coughing, waking up at night, and daytime limitations.
    • Part 2 (Parent/Caregiver-Completed, 3 Items): The caregiver responds to 3 questions on a 0 to 5 Likert scale evaluating daytime wheeze, daytime cough, and nighttime waking.
  • Scoring & Interpretation (Range: 0 to 27):
    • 20 to 27: Well Controlled asthma.
    • ≤19: Uncontrolled (Poorly Controlled) asthma.

3. Asthma Control Questionnaire (ACQ)

  • Developer: Dr. Elizabeth Juniper.
  • Target Population: Adults and children aged 6 years and older.
  • Recall Window: Past 1 week (7 days).
  • Structure: Available in several validated formats:
    • ACQ-7 (Full Version): 5 symptom items (night waking, morning symptoms, activity limitation, shortness of breath, wheezing) + SABA use + FEV1 % predicted (measured by spirometry).
    • ACQ-6: 5 symptom items + SABA use (without spirometry).
    • ACQ-5: 5 symptom items alone (ideal for epidemiological research or telephone screening).
  • Scoring & Interpretation (Range: 0.0 to 6.0): Items are scored from 0 (totally controlled) to 6 (severely uncontrolled). The final score is the mean (average) of all item responses.
    • ≤0.75: Well Controlled asthma.
    • 0.76 to 1.49: "Grey Zone" (Indeterminate Control)—the patient is neither clearly well controlled nor clearly uncontrolled.
    • ≥1.50: Poorly Controlled (Inadequately Controlled) asthma.
  • Minimal Clinically Important Difference (MCID): 0.5 points. A change of ≥0.5 indicates a clinically meaningful shift.

4. Asthma Therapy Assessment Questionnaire (ATAQ)

  • Structure: 20-item disease-management survey containing a 4-item self-administered Asthma Control Domain (assessing missed work/school, nocturnal awakenings, SABA use during physical activity, and perception of control).
  • Scoring: Scored from 0 to 4 based on the number of affirmative responses indicating control problems (0 = No control problems; 1–2 = Low to medium control problems; 3–4 = High control problems).

Comparison of Validated Asthma Control Questionnaires

InstrumentTarget Age CohortRecall PeriodNumber of ItemsScoring Methodology & RangeUncontrolled Cutoff ThresholdMinimal Clinically Important Difference (MCID)
Asthma Control Test (ACT)≥12 years & adultsPast 4 weeks5 itemsSum of scores (5 to 25 points)Score ≤193.0 points
Childhood ACT (c-ACT)4 to 11 yearsPast 4 weeks7 items (4 child + 3 parent)Sum of scores (0 to 27 points)Score ≤193.0 points
Asthma Control Questionnaire (ACQ)≥6 years & adultsPast 1 week5, 6, or 7 itemsMean average of items (0.0 to 6.0)Score ≥1.50 (≤0.75 is well controlled)0.5 points
Asthma Therapy Assessment Questionnaire (ATAQ)All ages (parent proxy <18)Past 4 weeks4 control itemsSum of positive risk indicators (0 to 4)Score ≥1 (Score 3–4 indicates high risk)Not formally defined as numeric scale

Clinical Action Triggers: Stepping Therapy Up or Down

Assessing control directly triggers clinical action according to the EPR-3 and GINA step-wise algorithms:

Clinical Management Algorithm Based on Assessed Control:

┌───────────────────────────┬───────────────────────────────────────────────────────────────┐
│ Control Level             │ Recommended Action & Follow-Up                                │
├───────────────────────────┼───────────────────────────────────────────────────────────────┤
│ Well Controlled           │ • Maintain current pharmacotherapy.                           │
│ (ACT ≥20, ACQ ≤0.75)      │ • Follow up in 1 to 6 months.                                 │
│                           │ • Consider STEPPING DOWN if well controlled for ≥3 months.    │
├───────────────────────────┼───────────────────────────────────────────────────────────────┤
│ Not Well Controlled       │ • STEP UP by 1 step.                                          │
│ (ACT 16–19, ACQ 0.76–1.49)│ • Re-evaluate in 2 to 6 weeks.                                │
│                           │ • Before stepping up: Check technique, adherence, triggers!   │
├───────────────────────────┼───────────────────────────────────────────────────────────────┤
│ Very Poorly Controlled    │ • Consider short course of Oral Systemic Corticosteroids.     │
│ (ACT ≤15, ACQ ≥1.50)      │ • STEP UP by 1 or 2 steps.                                    │
│                           │ • Re-evaluate in 2 weeks.                                     │
└───────────────────────────┴───────────────────────────────────────────────────────────────┘

Essential Educator Rule Before Stepping Up: Prior to escalating pharmacotherapy for a patient who is "Not Well Controlled," the asthma educator must systematically verify four non-pharmacologic determinants:

  1. Inhaler Technique: Are they loading and breathing the device correctly?
  2. Medication Adherence: Are they taking their daily controller as prescribed?
  3. Environmental Trigger Exposures: Has there been new allergen or irritant exposure (e.g., tobacco smoke, new pet)?
  4. Comorbid Conditions: Are untreated rhinitis, sinusitis, GERD, or obstructive sleep apnea exacerbating symptoms?
Test Your Knowledge

A 35-year-old male with persistent asthma on low-dose fluticasone-salmeterol attends a follow-up visit. He completes an Asthma Control Test (ACT) and scores 17. Spirometry reveals an FEV1 of 74% predicted, and he reports using his albuterol inhaler 4 days per week for breakthrough chest tightness. According to NHLBI EPR-3 guidelines, what is his control level and the appropriate clinical management?

A
B
C
D
Test Your Knowledge

An 8-year-old child completes the Childhood Asthma Control Test (c-ACT) with their mother. The combined score across the 4 child items and 3 parent items is 18. What does this score indicate regarding the child's asthma control, and what is the Minimal Clinically Important Difference (MCID) established for the standard Asthma Control Test (ACT)?

A
B
C
D
Test Your Knowledge

When utilizing Elizabeth Juniper's Asthma Control Questionnaire (ACQ) to monitor an adult patient receiving daily inhaled corticosteroid maintenance therapy, which mean score threshold confirms that the patient's asthma is inadequately controlled?

A
B
C
D